|
Advertise About
Subscribe
Live
TSX24,847▲ +0.44%
S&P 5005,612▲ +0.31%
Gold$3,342▼ −0.19%
BTC$108,240▲ 1.82%
WTI$78.40▲ +1.12%
USD/CAD1.3612▼ −0.08%
Silver$33.80▲ +0.62%
Uranium$92.50▲ +2.44%
TSX24,847▲ +0.44%
S&P 5005,612▲ +0.31%
Gold$3,342▼ −0.19%
BTC$108,240▲ 1.82%
WTI$78.40▲ +1.12%
USD/CAD1.3612▼ −0.08%
Silver$33.80▲ +0.62%
Uranium$92.50▲ +2.44%
Author: <span>Dr. Anaya Singh</span>

Author: <span>Dr. Anaya Singh</span>

Zymeworks Enters Phase 3 With Bispecific Antibody in HER2+ Gastric Cancer
Biotech
Zymeworks Enters Phase 3 With Bispecific Antibody in HER2+ Gastric Cancer
Dr. Anaya Singh · July 2, 2026
AbCellera’s AI Antibody Platform Has Now Discovered 120 Drug Candidates. Here’s the Scorecard.
Biotech
AbCellera’s AI Antibody Platform Has Now Discovered 120 Drug Candidates. Here’s the Scorecard.
Dr. Anaya Singh ·
CRISPR Therapeutics Is Selecting Canadian Sites for Its Sickle Cell and Beta-Thalassemia Programs
Biotech
CRISPR Therapeutics Is Selecting Canadian Sites for Its Sickle Cell and Beta-Thalassemia Programs
Dr. Anaya Singh ·
Lecanemab Approved in Canada for Early Alzheimer’s A Landmark Moment for Neuroscience Investors
Biotech
Lecanemab Approved in Canada for Early Alzheimer’s A Landmark Moment for Neuroscience Investors
Dr. Anaya Singh ·
Canada’s Biosimilar Market Reaches $2.4B as Patent Cliffs Accelerate Generic Competition
Biotech
Canada’s Biosimilar Market Reaches $2.4B as Patent Cliffs Accelerate Generic Competition
Dr. Anaya Singh · July 1, 2026
Three CSE-Listed Biotechs With Active Phase 2 Trials That Analysts Are Watching
Biotech
Three CSE-Listed Biotechs With Active Phase 2 Trials That Analysts Are Watching
Dr. Anaya Singh ·
Health Canada Approves Apobiologix Biosimilar What It Means for Drug Pricing
Biotech
Health Canada Approves Apobiologix Biosimilar What It Means for Drug Pricing
Dr. Anaya Singh ·
Liquid Biopsy Companies Are Racing Into Canada’s $1.2B Early Cancer Detection Market
Biotech
Liquid Biopsy Companies Are Racing Into Canada’s $1.2B Early Cancer Detection Market
Dr. Anaya Singh ·
Butterfly Network’s Handheld Ultrasound Is Reshaping Point-of-Care Diagnostics
Biotech
Butterfly Network’s Handheld Ultrasound Is Reshaping Point-of-Care Diagnostics
Dr. Anaya Singh · June 30, 2026
FDA-Health Canada Collaboration Is Cutting Drug Review Times by 18 Months
Biotech
FDA-Health Canada Collaboration Is Cutting Drug Review Times by 18 Months
Dr. Anaya Singh ·

The Boreal Brief

Canadian markets intelligence delivered every morning before the open. Free.